Cashu
Century Therapeutics Gains Insights from Clear Street's Expanded Biotechnology Research Initiative
11 months ago
Stocks
Health Care
ipsc
Century Therapeutics
NASDAQ: IPSC
+0.01 (+1.49%)
0.4714
USD
At close at Nov 14, 21:44 UTC
Overview
Loading chart...
Key Stats
Market Cap
40.80M
Dividend Yield
0.00%
P/E Ratio
-1.54
EPS
-1.63
Revenue
6.59M
Avg. Volume
1.07M
About
What does IPSC do?
Century Therapeutics, based in Philadelphia, develops off-the-shelf allogeneic cell therapies for cancer, employing 152 staff since its IPO on June 17, 2021. Its product candidates target various malignancies, including CNTY-101 and CNTY-102 for B-cell lymphoma.
Sector
💻 Health Care
IPO
CEO
Employees
145
Headquarters
Pennsylvania, USA
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.